Table 2.
MRI and reference test characteristics of studies included in the meta-analysis.
| Study | Magnet | Scanner/vendors | DWI scan | b-Values (1000 s/mm2) | Primary lesion segmentation | HPV test |
|---|---|---|---|---|---|---|
| Chan et al.8 | 1.5 and 3 T | TwinSpeed Excite, GE; and Achieva, Philips | EPI | 0, 1000 | Largest circular ROI excluding cystic/necrotic components on b0 images with attention to T1 and STIR | p16 immunohistochemistry (>70%) |
| De Perrot et al.9 | 1.5 and 3 T | — | SS SE EPI | 0, 1000 | The two largest consecutive cross-sectional tumor areas on axial b1000 and ADC maps | p16 immunohistochemistry (>70%) and PCR |
| Driessen et al.10 | 1.5 T | Intera NT, Philips | SS SE EPI | 0, 150, 800 | Whole tumor on b0 image with additional information from other MRI series | p16 immunohistochemistry (>70%) and PCR |
| Nakahira et al.25 | 1.5 T | Achieva Nova Dual, Philips | EPI | 0, 1000 | Single slice of ADC map containing the largest available tumor area | p16 Immunohistochemistry (>25%) |
| Wong et al.26 | 1.5 T | MAGNETOM Aera, Siemens | SE EPI | 50, 400, 800 | Whole tumor on b50 images with reference to anatomic contours, excluding necrosis and cysts | — |
EPI: echo planar imaging; PCR: polymerase chain reaction; SE: spin-echo; SS: single-shot.